Impact of IL28B, ITPA and PNPLA3 genetic variants on therapeutic outcome and progression of hepatitis C virus infection

• Chronic HCV infection comprises a broad spectrum of liver disease, ranging from no or minimal activity to active hepatitis that in time may progress to severe liver fibrosis, cirrhosis and hepatocellular carcinoma if left untreated. This review describes the impact of genetic variants of interleukin 28B (IL28B; also known as interferon-lambda 3), inosine triphosphate pyrophosphatase (ITPA) and patatin-like phospholipase domain-containing 3 (PNPLA3) on therapeutic outcome and liver disease severity in HCV-infected patients.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)

Nyckelord

genetic variant

HCV

histology

IL28B

inosine triphosphate pyrophosphatase

interferon-lambda

INOSINE TRIPHOSPHATE PYROPHOSPHATASE

FATTY LIVER-DISEASE

GENOME-WIDE

ASSOCIATION

INTERFERON-STIMULATED GENES

RIBAVIRIN THERAPY

PYROPHOSPHOHYDROLASE DEFICIENCY

SPONTANEOUS CLEARANCE

PEGYLATED

INTERFERON

HEMOLYTIC-ANEMIA

HCV CLEARANCE

Pharmacology & Pharmacy

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)